NiKang Therapeutics, Inc.

Merck & Co., Inc. stands to move the hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor Welireg (belzutifan) beyond its current indication of cancers associated with a rare genetic disorder, with re

Chinese biotechs' appetite for innovation remains strong despite valuations for the sector being hit hard by stock market turmoil. China’s Shanghai market comprehensive index has dived below 3,000 for

Venture capital firms focused on biopharmaceutical companies raised $810m across two new funds during the past two weeks, including $550m for venBio and Ysios Capital’s recently closed €216m ($260m) f

Erasca Inc. launched at the end of 2018 with $42m, a high-profile CEO and undisclosed precision oncology programs with the ambitious goal of “erasing cancer.” Even after raising another $200m in Apri